LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 23, 2022 | Last Trade: US$120.96 5.77 -4.55

AUSTIN, Texas, Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET).

Interested parties may access the live webcast of the presentation on the Natera Investor Relations website at investor.natera.com, where the webcast will be archived for future reference.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB